Clinical Use and Adverse Drug Reactions of Linezolid: A Retrospective Study in Four Belgian Hospital Centers

In Belgium, linezolid is indicated for pneumonia and skin and soft tissue infections, but is more broadly used, due to its oral bioavailability and activity against multiresistant organisms. This could increase the risk of adverse drug reactions (ADR), notably hematological disorders (anemia, thromb...

Full description

Saved in:
Bibliographic Details
Main Authors: Hélène Thirot (Author), Caroline Briquet (Author), Frédéric Frippiat (Author), Frédérique Jacobs (Author), Xavier Holemans (Author), Séverine Henrard (Author), Paul M. Tulkens (Author), Anne Spinewine (Author), Françoise Van Bambeke (Author)
Format: Book
Published: MDPI AG, 2021-05-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_9eba6b0283e3413ea56e37468faae65c
042 |a dc 
100 1 0 |a Hélène Thirot  |e author 
700 1 0 |a Caroline Briquet  |e author 
700 1 0 |a Frédéric Frippiat  |e author 
700 1 0 |a Frédérique Jacobs  |e author 
700 1 0 |a Xavier Holemans  |e author 
700 1 0 |a Séverine Henrard  |e author 
700 1 0 |a Paul M. Tulkens  |e author 
700 1 0 |a Anne Spinewine  |e author 
700 1 0 |a Françoise Van Bambeke  |e author 
245 0 0 |a Clinical Use and Adverse Drug Reactions of Linezolid: A Retrospective Study in Four Belgian Hospital Centers 
260 |b MDPI AG,   |c 2021-05-01T00:00:00Z. 
500 |a 10.3390/antibiotics10050530 
500 |a 2079-6382 
520 |a In Belgium, linezolid is indicated for pneumonia and skin and soft tissue infections, but is more broadly used, due to its oral bioavailability and activity against multiresistant organisms. This could increase the risk of adverse drug reactions (ADR), notably hematological disorders (anemia, thrombocytopenia), neuropathy, or lactic acidosis. We analyzed linezolid clinical use in relationship with occurrence of ADR in Belgian hospitals and highlighted risk factors associated with the development of thrombocytopenia. A retrospective analysis of electronic medical records and laboratory tests of adult patients treated with linezolid in four Belgian hospitals in 2016 allowed the collection of ADR for 248 linezolid treatments. Only 19.7% of indications were in-label. ADR included 43 thrombocytopenia, 17 anemia, 4 neuropathies, and 4 increases in lactatemia. In a multi-variate analysis, risk factors of thrombocytopenia were a treatment duration > 10 days, a glomerular filtration rate < 60 mL/min, and a Charlson index ≥ 4. Off-label use of linezolid is frequent in Belgium, and ADR more frequent than reported in the summary of product characteristics, but not statistically associated with any indication. This high prevalence of ADR could be related to a high proportion of patients presenting risk factors in our population, highlighting the importance of detecting them prospectively. 
546 |a EN 
690 |a linezolid 
690 |a adverse drug reaction 
690 |a thrombocytopenia 
690 |a anemia 
690 |a serotonin syndrome 
690 |a neuropathy 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Antibiotics, Vol 10, Iss 5, p 530 (2021) 
787 0 |n https://www.mdpi.com/2079-6382/10/5/530 
787 0 |n https://doaj.org/toc/2079-6382 
856 4 1 |u https://doaj.org/article/9eba6b0283e3413ea56e37468faae65c  |z Connect to this object online.